Iovance Biotherapeutics
IOVA
167 hedge funds and large institutions have $3B invested in Iovance Biotherapeutics in 2019 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 54 increasing their positions, 41 reducing their positions, and 30 closing their positions.
983% more call options, than puts
Call options by funds: $20.5M | Put options by funds: $1.9M
168% more capital invested
Capital invested by funds: $1.12B → $3B (+$1.88B)
71% more funds holding in top 10
Funds holding in top 10: 7 → 12 (+5)
57% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 30
32% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 41
9% more funds holding
Funds holding: 153 → 167 (+14)
3.87% more ownership
Funds ownership: 95.14% → 99.01% (+3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$71M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.5M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$41.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$24.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$24.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$18.5M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$15.1M |
IOVA Hedge Fund Activity: Q2 2019 in Review
167 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2019, worth a combined $3B — up 168% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new IOVA positions and 30 closed out — a net gain of 17 holders — while 54 added to existing stakes and 41 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $71M. The largest seller was Broadfin Capital, cutting an estimated $41.7M.
- 167 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2019, up from 153 in Q1 2019.
- Funds reported $3B of Iovance Biotherapeutics stock for Q2 2019, up 168% quarter-over-quarter.
- 47 funds opened new Iovance Biotherapeutics positions in Q2 2019 and 30 closed out, a net change of +17 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2019 was Consonance Capital Management, an estimated $71M added.
- The largest Iovance Biotherapeutics seller in Q2 2019 was Broadfin Capital, an estimated $41.7M sold.
Based on aggregated 13F filings for Q2 2019.